Qiming Corporate GP VI, Ltd., a 10% owner and director-affiliated entity of Alamar Biosciences, Inc. (NASDAQ:ALMR), filed a Form 4 on October 27, 2026, reporting the sale of common stock across multiple affiliated funds on October 23 and October 26, 2026.

Key Highlights

  • Multiple sales across two days: Transactions occurred on October 23 and October 26, 2026, with shares sold at weighted average prices ranging from $29.35 to $30.85 on the first day and $30.52 to $31.07 on the second.
  • Four affiliated funds involved: Sales were executed across Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC, and Qiming Venture Partners VIII-HC, L.P.
  • Remaining beneficial ownership after all transactions: Qiming Managing Directors Fund VI held 167,438 shares; Qiming Venture Partners VI held 6,222,616 shares; Qiming Venture Partners VIII Investments, LLC held 1,451,929 shares; and Qiming Venture Partners VIII-HC, L.P. held 1,738,295 shares.
  • All transactions coded "S": All reported transactions are open-market sales (Transaction Code S) of common stock disposed of (D).
  • Weighted average prices used: According to the filing, each reported price is a weighted average; shares were sold across price ranges, with the reporting person undertaking to provide full detail per-price upon request.
  • Indirect ownership: All shares are held indirectly through the listed fund entities; Qiming Corporate GP VI, Ltd. disclaims beneficial ownership except to the extent of its proportionate pecuniary interest.

Qiming-Affiliated Funds Reduce Alamar Biosciences Holdings Across Two Trading Days

According to the Form 4 filed with the SEC, Qiming Corporate GP VI, Ltd., acting as a reporting person and indirect general partner of multiple affiliated funds, reported sales of Alamar Biosciences, Inc. common stock on October 23 and October 26, 2026. The filing identifies seven reporting persons in total, all affiliated with the Qiming Venture Partners organization and all listed as 10% owners and director-affiliated parties of the issuer.

On October 23, 2026, the filing discloses sales across three price points: 107 shares at a weighted average of $29.35, 832 shares at $30.23, and 1,646 shares at $30.85 from Qiming Managing Directors Fund VI; 3,975 shares at $29.35, 30,921 shares at $30.23, and 61,191 shares at $30.85 from Qiming Venture Partners VI; 928, 7,215, and 14,277 shares at the same respective prices from Qiming Venture Partners VIII Investments, LLC; and 1,110, 8,638, and 17,094 shares from Qiming Venture Partners VIII-HC, L.P. On October 26, 2026, additional sales were reported at weighted average prices of $30.52 and $31.07 across all four fund entities.

The filing states that all prices are weighted averages and that shares were sold across stated price ranges. For example, the $29.35 weighted average covered transactions ranging from $28.605 to $29.56, and the $30.85 weighted average covered transactions from $30.62 to $31.335. All shares are held indirectly, and each general partner entity disclaims beneficial ownership except to the extent of its proportionate pecuniary interest, according to the filing.

What Was Disclosed

Qiming Corporate GP VI, Ltd. and affiliated Qiming entities filed a Form 4 disclosing sales of Alamar Biosciences common stock on October 23 and October 26, 2026, across four fund vehicles, with remaining indirect beneficial ownership totaling approximately 9.6 million shares combined across all funds.